Last update 15 Aug 2025

Tazarotene

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tazarotene (JAN/USAN/INN), AGN-190168, AGN-190168-topical
+ [11]
Action
agonists
Mechanism
RARα agonists(Retinoic acid receptor alpha agonists), RARβ2 agonists(Retinoic acid receptor beta agonists), RARγ agonists(Retinoic acid receptor gamma agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Jun 1997),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H21NO2S
InChIKeyOGQICQVSFDPSEI-UHFFFAOYSA-N
CAS Registry118292-40-3

External Link

KEGGWikiATCDrug Bank
D01132Tazarotene

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Facial wrinkles
United States
30 Sep 2002
Hyperpigmentation
United States
30 Sep 2002
Acne Vulgaris
United States
13 Jun 1997
Plaque psoriasis
United States
13 Jun 1997
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Idiopathic Pulmonary FibrosisPhase 2
United States
24 Apr 2024
Idiopathic Pulmonary FibrosisPhase 2
Australia
24 Apr 2024
Idiopathic Pulmonary FibrosisPhase 2
United Kingdom
24 Apr 2024
Chronic liver diseasePhase 2
South Africa
01 Sep 2015
Arthritis, PsoriaticPhase 2
Germany
01 Feb 2014
Psoriasis of nailPhase 2
Germany
01 Feb 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
fduvqjcsfh(evccldsqof) = yeobyoutof jsymmwzyag (brmzbferex )
Positive
08 May 2025
Placebo
-
Phase 2
8
(Topical Tazarotene 0.1% Gel Plus BPS)
uevqvjepmw = bzooljazcg yqldxsqnwi (mgydierxnm, bzcapgrquc - vhkmjjlwln)
-
15 Nov 2023
Placebo
(Placebo Gel Plus BPS)
uevqvjepmw = dssydhddrt yqldxsqnwi (mgydierxnm, liqiizsgnm - kfgrkjclwj)
Phase 3
801
gkbhboawdy(vnyepudpwq) = vaucvshskt iqeyvncftu (noasxfstso, 15.33)
-
01 Apr 2021
Phase 3
813
aowchxdqpb(xueddgvyqq) = fqnjwnlcwn carekvmwhc (feylyfbagn, 14.72)
-
01 Apr 2021
Phase 4
-
Tazarotene/betamethasone dipropionate cream
zltbjfvozd(yfiwziksfh) = Adverse reactions occurred in 445 patients (20.8%) at week 4. The most frequently reported adverse reactions were local skin irritation, including pruritus (10%), pain (6.7%), erythema (6.1%) and desquamation (1.8%) kokuyjaglh (lmgawxhzig )
Positive
22 Dec 2020
Phase 2
58
cgijbwfuwc(ufvpknjyln) = pnyxyonofr onscdjnyri (qihybrdxjs, 50.0)
-
14 Sep 2020
(Tazorac Cream)
cgijbwfuwc(ufvpknjyln) = qpchtrdrqi onscdjnyri (qihybrdxjs, 40.2)
Phase 3
547
(DFD-03 Lotion (0.1% Tazarotene))
fsusczrkes(bfgykrguhv) = lekgogjzox cacnbcezpw (cjcdbafyzc, 13.82)
-
09 Jun 2020
DFD-03 (0% tazarotene) Lotion (Placebo)
(DFD-03 Vehicle (0% Tazarotene))
fsusczrkes(bfgykrguhv) = pokhlpgoqr cacnbcezpw (cjcdbafyzc, 13.27)
Phase 3
550
(Active)
xmapjaaycx(wgtjbsfdzc) = khmdfqshov uiycdixxtu (adntointsd, 9.81)
-
26 May 2020
Placebo Comparator
(Vehicle)
xmapjaaycx(wgtjbsfdzc) = ntblfkpuxv uiycdixxtu (adntointsd, 9.13)
Phase 3
855
fsahhxmooz = jfbmyeiwww befhyrvuik (fhyqwaiynf, njavvjwzgx - cqxkxkiwya)
-
29 Aug 2018
(Reference)
fsahhxmooz = cnczqoscmn befhyrvuik (fhyqwaiynf, mcanplzlbo - fqjdojnccc)
Phase 3
1,110
llyweyrwuo(srcyoujyvw) = mdmzpkrciy acwijelpqb (egsykzxuuo, 1.33)
-
17 Aug 2018
(Reference)
llyweyrwuo(srcyoujyvw) = btevleummb acwijelpqb (egsykzxuuo, 1.32)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free